Gilead Sciences | DŁUG



Debt Zmiana Data
AbbVie USD 67.14B 3.94B 2024-12
Agios Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 0 0 2025-03
Alnylam Pharmaceuticals USD 1.03B 945K 2025-03
Amgen USD 57.38B 2.72B 2025-03
Biogen USD 6.3B 2M 2025-03
BioMarin Pharmaceutical USD 595.65M 585K 2025-03
Bristol-Myers Squibb USD 49.71B 62M 2025-03
Eli Lilly USD 38.52B 4.87B 2025-03
Gilead Sciences USD 26.71B 3.46B 2024-12
GlaxoSmithKline GBP 18.43B 1.45B 2025-03
Glaxosmithkline GBP 16.99B 927M 2024-12
Incyte USD 37.12M 840K 2025-03
J&J USD 52.25B 15.62B 2025-03
Merck USD 34.84B 2.27B 2025-03
Moderna USD 745M 683M 2025-03
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 31.26B 828M 2024-12
Pfizer USD 62.11B 2.24B 2025-03
PTC Therapeutics USD 2.4B 17.29M 2025-03
Regeneron Pharmaceuticals USD 2.7B 400K 2025-03
Sanofi 21.05B 3.14B 2025-03
Sarepta Therapeutics USD 1.14B 1.16M 2025-03
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Gilead Sciences DŁUG - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - May 2025.